These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32926834)

  • 1. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
    Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
    Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
    Zinsou JF; Diemert DJ; Dejon-Agobé JC; Adégbité BR; Honkpehedji YJ; Vodonou KG; Bikangui R; Edoa JR; Massinga Loembe M; Li G; Yazdanbakhsh M; Bottazzi ME; van Leeuwen R; Kremsner PG; Hotez PJ; Bethony JM; Grobusch MP; Adegnika AA
    Lancet Infect Dis; 2024 Jul; 24(7):760-774. PubMed ID: 38513684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
    Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005574. PubMed ID: 28464026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults.
    Diemert DJ; Zumer M; Campbell D; Grahek S; Li G; Peng J; Elena Bottazzi M; Hotez P; Bethony J
    Vaccine; 2022 Oct; 40(42):6084-6092. PubMed ID: 36114129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon.
    Mouwenda YD; Betouke Ongwe ME; Sonnet F; Stam KA; Labuda LA; De Vries S; Grobusch MP; Zinsou FJ; Honkpehedji YJ; Dejon Agobe JC; Diemert DJ; van Leeuwen R; Bottazzi ME; Hotez PJ; Kremsner PG; Bethony JM; Jochems SP; Adegnika AA; Massinga Loembe M; Yazdanbakhsh M
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009732. PubMed ID: 34597297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults.
    Bethony JM; Simon G; Diemert DJ; Parenti D; Desrosiers A; Schuck S; Fujiwara R; Santiago H; Hotez PJ
    Vaccine; 2008 May; 26(19):2408-17. PubMed ID: 18396361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial.
    Chapman PR; Webster R; Giacomin P; Llewellyn S; Becker L; Pearson MS; De Labastida Rivera F; O'Rourke P; Engwerda CR; Loukas A; McCarthy JS
    Lancet Infect Dis; 2021 Dec; 21(12):1725-1736. PubMed ID: 34419209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74.
    Pearson MS; Jariwala AR; Abbenante G; Plieskatt J; Wilson D; Bottazzi ME; Hotez PJ; Keegan B; Bethony JM; Loukas A
    Hum Vaccin Immunother; 2015; 11(5):1251-7. PubMed ID: 26018444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection.
    Shalash AO; Becker L; Yang J; Giacomin P; Pearson M; Hussein WM; Loukas A; Toth I; Skwarczynski M
    J Allergy Clin Immunol; 2022 Jul; 150(1):157-169.e10. PubMed ID: 35278494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
    Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths.
    Diemert DJ; Pinto AG; Freire J; Jariwala A; Santiago H; Hamilton RG; Periago MV; Loukas A; Tribolet L; Mulvenna J; Correa-Oliveira R; Hotez PJ; Bethony JM
    J Allergy Clin Immunol; 2012 Jul; 130(1):169-76.e6. PubMed ID: 22633322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.